Kristin Manning
Psychiatric/Mental Health · New Castle, INNPI 1245794114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alkermes, Inc. at 34.6% of the total. Reporting peaked in 2024 at $2,109 and has fallen 50.9% since, to $1,035 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$648
- Axsome Therapeutics, Inc.$423
- Supernus Pharmaceuticals, Inc.$394
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$366
- Lundbeck LLC$293
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,62099%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 73 | $1,966 |
| AbbVie | 54 | $648 |
| Axsome Therapeutics, Inc. | 18 | $423 |
| Supernus Pharmaceuticals, Inc. | 24 | $394 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $366 |
| Lundbeck LLC | 17 | $293 |
| Corium, LLC | 17 | $286 |
| Otsuka America Pharmaceutical, Inc. | 11 | $240 |
| Ironshore Pharmaceuticals Inc. | 10 | $184 |
| Neurocrine Biosciences, Inc. | 9 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Johnson & Johnson | 7 | $127 |
| Tris Pharma Inc | 6 | $101 |
| Indivior Inc. | 5 | $97 |
| Novartis | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Novo Nordisk | 2 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,850
- LYBALVI$732
- ARISTADA INITIO$228
- Auvelity$122
- VIVITROL$116
How this compares
$5,681 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 115 | $164,027 |
| AuvelityDextromethorphan Hbr/Bupropion | 106 | $159,272 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $46,216 |
| CaplytaLumateperone Tosylate | 12 | $19,611 |
| TrintellixVortioxetine Hydrobromide | 29 | $16,518 |
| BelsomraSuvorexant | 30 | $13,041 |
| QuviviqDaridorexant Hcl | 16 | $7,834 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,857 |
| Ramelteon | 35 | $6,625 |
| Lisdexamfetamine Dimesylate | 19 | $5,562 |
| Clomipramine Hcl | 79 | $5,445 |
| Modafinil | 62 | $5,208 |
| Lurasidone Hcl | 19 | $5,013 |
| DayvigoLemborexant | 14 | $4,658 |
| Vilazodone Hcl | 32 | $3,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $648 | $164,027115 claims |
| Axsome Therapeutics, Inc.Auvelity | $423 | $159,272106 claims |
| Alkermes, Inc.Lybalvi | $1,966 | $46,21627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $151 | $23,37546 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $366 | $19,61112 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $27 | $7,83416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in New Castle
- Barbara LoganNew Castle$6K
- Kimberly HuffNew Castle$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.